BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139. [PMID: 16456816 DOI: 10.1002/cncr.21678] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, Svane IM. Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma: A Clinical Phase 1/2 trial. Journal of Immunotherapy 2008;31:771-80. [DOI: 10.1097/cji.0b013e3181833818] [Cited by in Crossref: 76] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
2 Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R. Biomarkers in melanoma. Ann Oncol 2009;20 Suppl 6:vi8-13. [PMID: 19617299 DOI: 10.1093/annonc/mdp251] [Cited by in Crossref: 84] [Cited by in F6Publishing: 80] [Article Influence: 6.5] [Reference Citation Analysis]
3 Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy: melanoma. J Skin Cancer 2011;2011:274382. [PMID: 22220281 DOI: 10.1155/2011/274382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
5 Ma B, Herzog EL, Moore M, Lee CM, Na SH, Lee CG, Elias JA. RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Sci Rep 2016;6:26299. [PMID: 27198666 DOI: 10.1038/srep26299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
6 Harving ML, Christensen LH, Ringsholt M, Lausten GS, Petersen MM. YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. Acta Orthop 2014;85:195-200. [PMID: 24650028 DOI: 10.3109/17453674.2014.893496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
7 Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456-4468. [PMID: 19767768 DOI: 10.1038/onc.2009.292] [Cited by in Crossref: 168] [Cited by in F6Publishing: 178] [Article Influence: 12.9] [Reference Citation Analysis]
8 Ranok A, Khunkaewla P, Suginta W. Human cartilage chitinase 3-like protein 2: cloning, expression, and production of polyclonal and monoclonal antibodies for osteoarthritis detection and identification of potential binding partners. Monoclon Antib Immunodiagn Immunother 2013;32:317-25. [PMID: 24111862 DOI: 10.1089/mab.2013.0016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Kzhyshkowska J, Gratchev A, Goerdt S. Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer. Biomark�Insights 2007;2:117727190700200. [DOI: 10.1177/117727190700200023] [Cited by in Crossref: 115] [Cited by in F6Publishing: 51] [Article Influence: 23.0] [Reference Citation Analysis]
10 Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-863. [PMID: 17957792 DOI: 10.1002/ijc.23152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
11 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
12 Weide B, Allgaier N, Hector A, Forschner A, Leiter U, Eigentler TK, Garbe C, Hartl D. Increased CCL17 serum levels are associated with improved survival in advanced melanoma. Cancer Immunol Immunother 2015;64:1075-82. [PMID: 25990074 DOI: 10.1007/s00262-015-1714-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
13 Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res 2016;26:367-76. [PMID: 27076041 DOI: 10.1097/CMR.0000000000000237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
14 Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol. 2011;13:1244-1251. [PMID: 21831900 DOI: 10.1093/neuonc/nor117] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
15 Ismail H, Helby J, Hölmich LR, Chakera AH, Bastholt L, Klyver H, Sjøgren P, Schmidt H, Schöllhammer L, Johansen JS, Nordestgaard BG, Bojesen SE. Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. Eur J Cancer 2019;121:74-84. [PMID: 31563729 DOI: 10.1016/j.ejca.2019.08.025] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
17 Specjalski K, Jassem E. YKL-40 protein is a marker of asthma. J Asthma 2011;48:767-72. [PMID: 21899483 DOI: 10.3109/02770903.2011.611955] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
18 Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front Oncol 2014;4:383. [PMID: 25667918 DOI: 10.3389/fonc.2014.00383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
19 Kzhyshkowska J, Larionova I, Liu T. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer. Front Immunol 2019;10:2930. [PMID: 32038607 DOI: 10.3389/fimmu.2019.02930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Salamon J, Hoffmann T, Elies E, Peldschus K, Johansen JS, Lüers G, Schumacher U, Wicklein D. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One 2014;9:e95822. [PMID: 24752554 DOI: 10.1371/journal.pone.0095822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
21 Kim KC, Yun J, Son DJ, Kim JY, Jung JK, Choi JS, Kim YR, Song JK, Kim SY, Kang SK, Shin DH, Roh YS, Han SB, Hong JT. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics 2018;8:4409-28. [PMID: 30214629 DOI: 10.7150/thno.26467] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
22 Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435-442. [PMID: 17023034 DOI: 10.1016/j.ygyno.2006.08.028] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
23 Revythis A, Shah S, Kutka M, Moschetta M, Ozturk MA, Pappas-Gogos G, Ioannidou E, Sheriff M, Rassy E, Boussios S. Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics (Basel) 2021;11:1341. [PMID: 34441278 DOI: 10.3390/diagnostics11081341] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 2011;32:1155-61. [PMID: 21858537 DOI: 10.1007/s13277-011-0218-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
25 Kim SH, Das K, Noreen S, Coffman F, Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 2007;5:17. [PMID: 17286869 DOI: 10.1186/1477-7819-5-17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
26 Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 2013;57:99-105. [PMID: 24222276 DOI: 10.1007/s12026-013-8459-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
27 Clement E, Lazar I, Muller C, Nieto L. Obesity and melanoma: could fat be fueling malignancy? Pigment Cell Melanoma Res 2017;30:294-306. [PMID: 28222242 DOI: 10.1111/pcmr.12584] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
28 Yang JD, Kim E, Pedersen RA, Kim WR, Pungpapong S, Roberts LR. Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver 2010;4:537-42. [PMID: 21253305 DOI: 10.5009/gnl.2010.4.4.537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
29 Itik V, Kemik O, Kemik A, Dulger AC, Sümer A, Soyoral YU, Begenik H, Purisa S, Kotan C. Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer 2011;3:25-30. [PMID: 24179388 DOI: 10.4137/BIC.S7154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
30 Samoilova DV, Kovaleva OV, Shelekhova KV, Petrenko AA, Kurochkin SN, Fedotov RV, Gratchev A. Development and Characterization of a Novel Monoclonal Antibody Against Chitinase-like Protein CHID1 Applicable for Immunohistochemistry on Formalin Fixed Paraffin-Embedded Sections. Monoclon Antib Immunodiagn Immunother 2019;38:12-7. [PMID: 30657411 DOI: 10.1089/mab.2018.0039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opinion on Therapeutic Targets 2007;11:219-34. [DOI: 10.1517/14728222.11.2.219] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
32 Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol. 2007;25:1562-1569. [PMID: 17443000 DOI: 10.1200/jco.2006.09.0274] [Cited by in Crossref: 138] [Cited by in F6Publishing: 61] [Article Influence: 9.2] [Reference Citation Analysis]
33 Al-Shaer M, Gollapudi D, Papageorgio C. Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett 2010;1:399-405. [PMID: 22966315 DOI: 10.3892/ol_00000070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
34 Neagu M, Constantin C, Manda G, Margaritescu I. Biomarkers of metastatic melanoma. Biomark Med 2009;3:71-89. [PMID: 20477497 DOI: 10.2217/17520363.3.1.71] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
35 Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE. Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population. Int J Cancer 2015;137:2696-704. [PMID: 26095694 DOI: 10.1002/ijc.29638] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
36 Malaguarnera G, Madeddu R, Catania VE, Bertino G, Morelli L, Perrotta RE, Drago F, Malaguarnera M, Latteri S. Anorectal mucosal melanoma. Oncotarget 2018;9:8785-800. [PMID: 29492238 DOI: 10.18632/oncotarget.23835] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
37 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. J Urol 2016;195:1120-5. [PMID: 26454102 DOI: 10.1016/j.juro.2015.09.084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
38 Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007;20:80-91. [PMID: 17371435 DOI: 10.1111/j.1600-0749.2006.00356.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
39 Guo Y, Hong W, Zhang P, Han D, Fang Y, Tu J, Wei W. Abnormal polarization of macrophage-like cells in the peripheral blood of patients with glioma. Oncol Lett 2020;20:947-54. [PMID: 32566024 DOI: 10.3892/ol.2020.11602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008;25:801-9. [PMID: 18670741 DOI: 10.1007/s12325-008-0082-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
41 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
42 Mouawad R, Spano JP, Khayat D. Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res. 2010;20:67-76. [PMID: 20093989 DOI: 10.1097/cmr.0b013e328335a8c1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
43 Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2014;35:277-86. [PMID: 23918300 DOI: 10.1007/s13277-013-1036-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
44 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
45 Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res 2015;75:487-96. [PMID: 25511377 DOI: 10.1158/0008-5472.CAN-13-3339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
46 Tandler N, Mosch B, Pietzsch J. Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids 2012;43:2203-30. [DOI: 10.1007/s00726-012-1409-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
47 Roslind A, Johansen JS, Junker N, Nielsen DL, Dzaferi H, Price PA, Balslev E. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl Immunohistochem Mol Morphol 2007;15:371-81. [PMID: 18091378 DOI: 10.1097/01.pai.0000213146.77772.6a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
48 Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 2015;54:961-70. [PMID: 25984930 DOI: 10.3109/0284186X.2015.1043026] [Cited by in Crossref: 107] [Cited by in F6Publishing: 70] [Article Influence: 15.3] [Reference Citation Analysis]
49 Kacira T, Hanimoglu H, Kucur M, Sanus GZ, Kafadar AM, Tanriverdi T, Kaynar MY. Elevated cerebrospinal fluid and serum YKL-40 levels are not associated with symptomatic vasospasm in patients with aneurysmal subarachnoid haemorrhage. J Clin Neurosci 2008;15:1011-6. [PMID: 18280741 DOI: 10.1016/j.jocn.2006.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
50 Ugurel S, Utikal J, Becker JC. Tumor Biomarkers in Melanoma. Cancer Control 2009;16:219-24. [DOI: 10.1177/107327480901600303] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
51 Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urologic Oncology: Seminars and Original Investigations 2014;32:663-9. [DOI: 10.1016/j.urolonc.2014.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
52 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
53 Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56:1485-99. [PMID: 17285289 DOI: 10.1007/s00262-007-0293-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 4.5] [Reference Citation Analysis]
54 Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP. Circulating glioma biomarkers. Neuro Oncol 2015;17:343-60. [PMID: 25253418 DOI: 10.1093/neuonc/nou207] [Cited by in Crossref: 25] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
55 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
56 Lee YS, Yu JE, Kim KC, Lee DH, Son DJ, Lee HP, Jung JK, Kim ND, Ham YW, Yun J, Han SB, Hong JT. A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals. Mol Oncol 2021. [PMID: 34758182 DOI: 10.1002/1878-0261.13138] [Reference Citation Analysis]
57 Luo D, Chen H, Lu P, Li X, Long M, Peng X, Huang M, Huang K, Lin S, Tan L, Zhu Y, Chen Z, Ouyang N, Li H. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma. Cancer Biomark 2017;18:273-84. [PMID: 28009325 DOI: 10.3233/CBM-160255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
58 Utikal J, Schadendorf D, Ugurel S. Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res. 2007;298:469-477. [PMID: 17221215 DOI: 10.1007/s00403-006-0726-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
59 Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 2012;48:695-702. [PMID: 21917447 DOI: 10.1016/j.ejca.2011.08.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
60 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
61 Ramos-Espinosa G, Wang Y, Brandner JM, Schneider SW, Gorzelanny C. Melanoma Associated Chitinase 3-Like 1 Promoted Endothelial Cell Activation and Immune Cell Recruitment. Int J Mol Sci 2021;22:3912. [PMID: 33920100 DOI: 10.3390/ijms22083912] [Reference Citation Analysis]
62 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
63 Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer. 2010;10:593. [PMID: 21029458 DOI: 10.1186/1471-2407-10-593] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
64 Rappu P, Nylund C, Ristiniemi N, Kulpakko J, Vihinen P, Hernberg M, Mirtti T, Alanen K, Kallajoki M, Vuoristo MS, Pyrhönen S, Heino J. Detection of melanoma-derived cancer-testis antigen CT16 in patient sera by a novel immunoassay. Int J Cancer 2011;128:2382-92. [PMID: 20658534 DOI: 10.1002/ijc.25571] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
65 He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, Ma B, Herzog EL, Rosenberg SA, Li Y. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep. 2013;4:830-841. [PMID: 23972995 DOI: 10.1016/j.celrep.2013.07.032] [Cited by in Crossref: 161] [Cited by in F6Publishing: 157] [Article Influence: 17.9] [Reference Citation Analysis]
66 Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X, Tamiya T. Association between YKL-40 and adult primary astrocytoma. Cancer 2010;116:2688-97. [PMID: 20499402 DOI: 10.1002/cncr.25084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
67 Kanwar JR, Singh N, Kanwar RK. Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine 2011;6:701-14. [DOI: 10.2217/nnm.11.48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
68 Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest 2021;131:e137750. [PMID: 34720089 DOI: 10.1172/JCI137750] [Reference Citation Analysis]
69 Qin W, Zhu W, Schlatter L, Miick R, Loy TS, Atasoy U, Hewett JE, Sauter ER. Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int J Cancer 2007;121:1536-42. [PMID: 17565739 DOI: 10.1002/ijc.22881] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
70 Karataş S, Şal V, Kahramanoğlu İ, Demirkıran F, Beşe T, Arvas M, Sofiyeva N, Güralp O, Uzun H. Ykl-40 and cancer antigen 72-4 as new and promising diagnostic and prognostic markers for endometrial cancer. Turk J Obstet Gynecol 2018;15:235-42. [PMID: 30693139 DOI: 10.4274/tjod.77906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
71 Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21. [PMID: 20564116 DOI: 10.1002/cncr.25196] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
72 Zhu CB, Chen LL, Tian JJ, Su L, Wang C, Gai ZT, Du WJ, Ma GL. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery. Ann Surg Oncol. 2012;19:817-825. [PMID: 21861215 DOI: 10.1245/s10434-011-2026-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
73 Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M, Saygılı U. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol 2016;140:64-9. [PMID: 26607777 DOI: 10.1016/j.ygyno.2015.11.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
74 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
75 Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40:1790-1797. [PMID: 19765801 DOI: 10.1016/j.humpath.2009.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
76 Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci. 2008;45:531-562. [PMID: 19003601 DOI: 10.1080/10408360802334743] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
77 Erturk K, Tas F, Serilmez M, Bilgin E, Yasasever V. Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients. Asian Pac J Cancer Prev 2017;18:1383-7. [PMID: 28612591 DOI: 10.22034/APJCP.2017.18.5.1383] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
78 Shantha Kumara HMC, Gaita D, Miyagaki H, Yan X, Hearth SA, Njoh L, Cekic V, Whelan RL. Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection. World J Gastrointest Oncol 2016; 8(8): 607-614 [PMID: 27574553 DOI: 10.4251/wjgo.v8.i8.607] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
79 Rani R, Singh V. Overexpression of YKL-40 (CHI3L1 gene) in patient fluids may be a potential predictive marker for early detection of comorbidity in non-communicable disease. Med Hypotheses 2020;143:110076. [PMID: 32721792 DOI: 10.1016/j.mehy.2020.110076] [Reference Citation Analysis]
80 Bereman MS, Beri J, Enders JR, Nash T. Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS. Sci Rep 2018;8:16334. [PMID: 30397248 DOI: 10.1038/s41598-018-34642-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]